(VIANEWS) – John Hancock Premium Dividend Fund (PDT), Caesarstone Ltd. (CSTE), Eaton vance Floating (EFF) are the highest dividend yield stocks on this list.

Rank Financial Asset Price Change Forward Dividend Yield Updated (EST)
1 John Hancock Premium Dividend Fund (PDT) 17.12 0.45% 6.94% 2021-07-09 22:05:14
2 Caesarstone Ltd. (CSTE) 14.06 2.4% 5.65% 2021-07-10 18:06:09
3 Eaton vance Floating (EFF) 16.33 -0.5% 4.41% 2021-07-09 04:47:05
4 Pfizer (PFE) 39.61 0.92% 3.98% 2021-07-09 15:39:13

Close to 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. John Hancock Premium Dividend Fund (PDT) – Dividend Yield: 6.94%

John Hancock Premium Dividend Fund is a closed ended equity mutual fund launched and managed by John Hancock Investment Management LLC. It is co-managed by John Hancock Asset Management. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating across diversified sectors, with an emphasis on the utilities sector. The fund primarily invests in dividend paying preferred stocks and common stocks of companies. It benchmarks the performance of its portfolio against a composite benchmark comprised of 70% Bank of America Merrill Lynch Preferred Stock DRD Eligible Index and 30% S&P 500 Utilities Index. The fund was formerly known as John Hancock Patriot Premium Dividend Fund II. John Hancock Premium Dividend Fund was formed on December 21, 1989 and is domiciled in the United States.

Volume

Today’s last reported volume for John Hancock Premium Dividend Fund is 70520, 29.19% below its average volume of 99590.

John Hancock Premium Dividend Fund’s last close was $16.52, 5.06% below its 52-week high of $17.40.

John Hancock Premium Dividend Fund’s Revenue

Year-on-year quarterly revenue growth declined by 4.8%, now sitting on 55.4M for the twelve trailing months.

John Hancock Premium Dividend Fund’s Stock Yearly Top and Bottom Value

John Hancock Premium Dividend Fund’s stock is valued at $17.12 at 17:15 EST, under its 52-week high of $17.40 and way higher than its 52-week low of $12.00.

John Hancock Premium Dividend Fund’s Moving Average

John Hancock Premium Dividend Fund’s value is above its 50-day moving average of $16.91 and way higher than its 200-day moving average of $15.15.

More news about John Hancock Premium Dividend Fund.

2. Caesarstone Ltd. (CSTE) – Dividend Yield: 5.65%

Caesarstone Ltd., together with its subsidiaries, develops, manufactures, and markets engineered quartz surfaces under the Caesarstone brand in the United States, Australia, Canada, Israel, Europe, and internationally. Its engineered quartz slabs are primarily used as kitchen countertops in the renovation and remodeling markets, as well as in new buildings construction market. The company's products are also used in other applications, such as vanity tops, wall panels, back splashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. It sells its products directly to fabricators, sub-distributors, and resellers; and indirectly through a network of independent distributors. The company was formerly known as Caesarstone Sdot Yam Ltd. and changed its name to Caesarstone Ltd. in June 2016. Caesarstone Ltd. was founded in 1987 and is headquartered in MP Menashe, Israel.

Volume

Today’s last reported volume for Caesarstone Ltd. is 48052, 66.84% below its average volume of 144895.

Caesarstone Ltd.’s last close was $16.50, 16.67% under its 52-week high of $19.80.

Caesarstone Ltd.’s Sales

Caesarstone Ltd.’s sales growth is 47.1% for the ongoing quarter and 27% for the next. The company’s growth estimates for the current quarter is a negative 50% and positive 30.8% for the next.

Caesarstone Ltd.’s Revenue

Year-on-year quarterly revenue growth grew by 15.4%, now sitting on 505.89M for the twelve trailing months.

Caesarstone Ltd.’s Stock Yearly Top and Bottom Value

Caesarstone Ltd.’s stock is valued at $14.06 at 17:15 EST, way below its 52-week high of $19.80 and way higher than its 52-week low of $9.23.

Caesarstone Ltd.’s Moving Average

Caesarstone Ltd.’s value is under its 50-day moving average of $15.44 and under its 200-day moving average of $14.06.

More news about Caesarstone Ltd..

3. Eaton vance Floating (EFF) – Dividend Yield: 4.41%

Eaton Vance Floating-Rate Income Plus Fund is a close ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in fixed income markets across the globe. The fund primarily invests in senior, secured floating-rate loans of domestic and foreign borrowers that are denominated in U.S. dollars as well as foreign currencies. Eaton Vance Floating-Rate Income Plus Fund was formed on June 28, 2013 and is domiciled in the United States.

Volume

Today’s last reported volume for Eaton vance Floating is 167936, 408.2% above its average volume of 33045.

Eaton vance Floating’s last close was $16.38, 1.21% below its 52-week high of $16.58.

Eaton vance Floating’s Stock Yearly Top and Bottom Value

Eaton vance Floating’s stock is valued at $16.33 at 17:15 EST, below its 52-week high of $16.58 and way above its 52-week low of $13.46.

Eaton vance Floating’s Moving Average

Eaton vance Floating’s value is below its 50-day moving average of $16.40 and above its 200-day moving average of $16.06.

More news about Eaton vance Floating.

4. Pfizer (PFE) – Dividend Yield: 3.98%

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; and a multi-target drug discovery collaboration with Sosei Group Corporation. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Volume

Today’s last reported volume for Pfizer is 17807100, 32.21% below its average volume of 26268300.

Pfizer’s last close was $39.25, 8.89% under its 52-week high of $43.08.

Pfizer’s Sales

Pfizer’s sales growth is 58.9% for the present quarter and 62.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 25.6% and 44.4%, respectively.

Pfizer’s Revenue

Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pfizer’s stock is considered to be overbought (>=80).

Pfizer’s Stock Yearly Top and Bottom Value

Pfizer’s stock is valued at $39.61 at 17:15 EST, below its 52-week high of $43.08 and way higher than its 52-week low of $31.77.

Pfizer’s Moving Average

Pfizer’s worth is higher than its 50-day moving average of $39.33 and above its 200-day moving average of $37.28.

Previous days news about Pfizer

Pfizer plans to request FDA nod for covid booster in August. According to Bloomberg Quint on Thursday, 8 July, "As of July 1, Pfizer said it had shipped more than 860 million doses of its vaccine around the world, including over 330 million doses to the EU and over 200 million doses to the U.S.", "Separately, Pfizer plans to begin human trials of a new booster customized against the delta strain. "

Pfizer says Covid-19 booster shot data coming in August, not July. According to MarketWatch on Friday, 9 July, "Shares of Pfizer Inc. gained 1.9% in trading on Friday, the day after the company put out a statement saying it plans to share clinical data for its experimental COVID-19 booster shot in August. "

: U.S. drug regulators unmoved by Pfizer plan to seek covid booster authorization. According to MarketWatch on Friday, 9 July, "In an unusual exchange, the Food and Drug Administration and the Center for Disease Control on Thursday said there isn’t scientific evidence that COVID-19 booster shots are required, hours after drug maker Pfizer said it would seek authorization for a Covid booster shot to help contain the Delta variant."

Why shares of Pfizer are rising today. According to The Motley Fool on Friday, 9 July, "While Pfizer and BioNTech have billions to gain if the boosters are authorized, the Food and Drug Administration, the Centers for Disease Control and Prevention, and the National Institutes of Health have called for scientific rigor. "

Australia secures extra Pfizer jabs in bid to beat outbreaks. According to Bloomberg Quint on Thursday, 8 July, "Prime Minister Scott Morrison said his government has negotiated with Pfizer Inc. for millions of coronavirus vaccine doses to be delivered ahead of previous schedules, with the aim of offering every Australian at least one jab by the end of the year.", "Morrison’s spokesperson said the increased Pfizer doses come with a caveat: "Due to the nature of pandemic vaccine supply, these numbers are subject to change and will be confirmed closer to the delivery date."

More news about Pfizer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here